Clinical trials: Chronic Phase of Disease
Chronic Lung Disease
Study to Assess the Immune Reactivity of the Liquid and Lyophilized Formulations of Palivizumab (MEDI-493, Synagis)
The purpose of this study is to measure the rate of anti-palivizumab antibodies (also referred to as immune reactivity or immunogenicity) in subjects receiving either the liquid or lyophilized formulation of palivizumab.
- Trial name
- NCT00233064
- Testing
- Lyophilized Palivizumab, Liquid Palivizumab
- Where
- 54 sites in United States
- Volunteers
- 417 people
- Sponsor
- MedImmune LLC
Chronic Graft-versus-host Disease
Daily IL-2 for Steroid-Refractory Chronic Graft-versus-Host-Disease
Chronic GVHD is a medical condition that may occur after a bone marrow, stem cell or cord blood transplant. The donor's immune system may recognize the your body (the host) as foreign and attempt to 'reject' it.
- Trial name
- NCT01366092
- Testing
- Interleukin-2
- Where
- 3 sites in United States
- Volunteers
- 35 people
- Sponsor
- Dana-Farber Cancer Institute
Chronic Renal Failure
A Phase 2, Multi-center, Open-label, Dose-finding Trial to Investigate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of OPC-41061 in Patients With Chronic Renal Failure Undergoing Hemodialysis or Hemodiafiltration
To investigate the safety, pharmacokinetics, pharmacodynamics, and efficacy of OPC-41061 in patients with chronic renal failure undergoing hemodialysis or hemodiafiltration using variables, such as daily urine volume and increase…
- Trial name
- NCT01876381
- Testing
- OPC-41061
- Where
- 5 sites in Japan
- Volunteers
- 26 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
End-stage Renal Disease (ESRD)
A Study of ISIS 416858 Administered Subcutaneously to Participants With End-Stage Renal Disease (ESRD) on Hemodialysis
Evaluation of safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of ISIS 416858 for up to 204 participants with ESRD receiving chronic hemodialysis as assessed by FXI activity reduction.
- Trial name
- EMERALD (NCT03358030)
- Testing
- ISIS 416858
- Where
- 2 sites in Spain
- Volunteers
- 213 people
- Sponsor
- Ionis Pharmaceuticals, Inc.
Chronic Lymphocytic Leukemia
Dasatinib in Relapsed Chronic Lymphocytic Leukemia
The purpose of this research study is to see if Dasatinib is effective and safe to give to people with relapsed chronic lymphocytic leukemia (CLL) and to determine the effects of the drug on LYN kinase activity in blood and bone…
- Trial name
- NCT00438854
- Testing
- Dasatinib
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- Massachusetts General Hospital
Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
Sorafenib and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma
RATIONALE: Sorafenib and everolimus may stop the growth of cancer cells by blocking blood flow to the cancer and by blocking some of the enzymes needed for cell growth.
- Trial name
- NCT00474929
- Testing
- RAD001, Sorafenib
- Where
- 2 sites in United States
- Volunteers
- 103 people
- Sponsor
- Mayo Clinic
Chronic Lymphocytic Leukemia
FCR Versus FC Alone in the Treatment of Chronic Lymphocytic Leukemia (CLL) in Relapsed Patients
The purpose of this study is to provide treatment for patients who have chronic lymphocytic leukemia (CLL), and to compare the use of rituximab added to fludarabine+cyclophosphamide (FC) with FC alone, to determine if rituximab…
- Trial name
- NCT00090051
- Testing
- Rituximab, Fludarabine Phosphate, Cyclophosphamide
- Where
- 106 sites in United States, Australia and 15 more
- Volunteers
- 552 people
- Sponsor
- Hoffmann-La Roche
Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma
A Phase I/II Study of Intratumoral Injection of SD-101
This phase 1-2 trial studies the side effects and best dose of ipilimumab in combination with toll-like receptor 9 (TLR9) agonist SD-101 and radiation therapy in treating patients with recurrent low-grade B-cell lymphoma.
- Conditions
- Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma
- Trial name
- NCT02254772
- Testing
- Ipilimumab, SD-101, Radiation therapy
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Robert Lowsky
Leukemia
American Ginseng Extract in Preventing Respiratory Infection and in Reducing Antibiotic Use in Patients With CLL
RATIONALE: American ginseng extract may prevent or reduce acute respiratory illness in patients with chronic lymphocytic leukemia.
- Trial name
- NCT00752895
- Testing
- American ginseng
- Where
- 125 sites in United States
- Volunteers
- 293 people
- Sponsor
- Wake Forest University Health Sciences
Myeloid Leukemia, Chronic
Imatinib Mesylate and Zoledronic Acid in Patients With Chronic Myeloid Leukaemia in Cytogenetic Response Without Molecular Response
Imatinib mesylate is standard treatment of Chronic myeloid leukaemia, complete cytogenetic response is obtained in most of cases but molecular response concerned only a small part of the patients.
- Trial name
- AFR22 (NCT00210119)
- Testing
- Glivec
- Where
- 7 sites in France
- Volunteers
- 19 people
- Sponsor
- Institut Bergonié
Chronic Obstructive Pulmonary Disease, COPD
A Single-dose Study to Investigate the Effects of 4 Different Doses of Inhaled AZD8683 in Chronic Obstructive Pulmonary Disease (COPD) Patients
This study in Chronic Obstructive Pulmonary Disease (COPD) patients will investigate the bronchodilatory effect of AZD8683. AZD8683 will be tested versus placebo and an active comparator.
- Trial name
- NCT01708057
- Testing
- AZD8683, Tiotropium
- Where
- 6 sites in Poland, Sweden
- Volunteers
- 3 people
- Sponsor
- AstraZeneca
Chronic Stable Angina
Phase II Study of STA-2 in Patients With Chronic Stable Angina
The objectives of this study are to evaluate the efficacy, pharmacological activities and safety of STA-2 in the treatment of chronic stable angina.
- Trial name
- NCT01484912
- Testing
- STA-2
- Where
- 3 sites in Taiwan
- Volunteers
- 79 people
- Sponsor
- Sinphar Pharmaceutical Co., Ltd
Cardiovascular Diseases, Cardiovascular Abnormalities
Effect of SNF472 on Progression of Cardiovascular Calcification in End-Stage-Renal-Disease (ESRD) Patients on Hemodialysis (HD)
The primary objective is to assess the effect of 2 dose levels of SNF472 (300 mg and 600 mg) compared to placebo on the progression of coronary artery calcium volume score over a 12-month (52 weeks) period in ESRD patients on HD
- Conditions
- Cardiovascular Diseases, Cardiovascular Abnormalities, Calcifications, Vascular, Endstage Renal Disease
- Trial name
- NCT02966028
- Testing
- SNF472
- Where
- 75 sites in United States, Spain and 1 more
- Volunteers
- 274 people
- Sponsor
- Sanifit Therapeutics S. A.
Heart Failure
EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Reduced Ejection Fraction (EMPEROR-Reduced)
The aim of the study is to investigate the safety and efficacy of empagliflozin versus placebo on top of guideline-directed medical therapy in patients with heart failure with reduced ejection fraction.
- Trial name
- NCT03057977
- Testing
- Empagliflozin
- Where
- 520 sites in United States, Argentina and 18 more
- Volunteers
- 3,730 people
- Sponsor
- Boehringer Ingelheim
Kidney Diseases, Coronary Artery Disease
A Study of the Safety and Tolerance of Regadenoson in Subjects With Renal Impairment
This study is intended to assess the safety and tolerance of regadenoson in subjects with renal impairment.
- Trial name
- NCT00863707
- Testing
- Regadenoson
- Where
- 41 sites in United States
- Volunteers
- 511 people
- Sponsor
- Astellas Pharma Inc
Moderate to Severe Psoriasis, Generalized Pustular Psoriasis and Erythrodermic Psoriasis
A Study to Test the Efficacy and Safety of Certolizumab Pegol in Japanese Subjects With Moderate to Severe Chronic Psoriasis
The purpose of this study is to demonstrate the efficacy and safety of Certolizumab Pegol (CZP) in the treatment of moderate to severe chronic plaque Psoriasis (PSO) in Japanese subjects.
- Trial name
- NCT03051217
- Testing
- Certolizumab Pegol
- Where
- 33 sites in Japan
- Volunteers
- 127 people
- Sponsor
- UCB Biopharma S.P.R.L.
Chronic Lymphocytic Leukemia
Ibrutinib and PD-1 Blockade in High Risk Lymphocytic Leukemia
The purpose of this study is to evaluate the impact of sequential overlapping treatment with PD-1 monoclonal antibody (mAb), pembrolizumab/MK-1375, followed by ibrutinib on endogenous immune function in previously untreated…
- Trial name
- NCT03514017
- Testing
- Pembrolizumab, Ibrutinib
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Hepatitis C Virus Infection
Safety and Efficacy of Sofosbuvir + Ribavirin in Adolescents and Children With Genotype 2 or 3 Chronic HCV Infection
This study will have two parts as follows: The PK Lead-in Phase of the study will evaluate the steady state pharmacokinetics (PK) and confirm the dose of sofosbuvir (SOF) in hepatitis C virus (HCV)-infected pediatric…
- Trial name
- NCT02175758
- Testing
- SOF, RBV
- Where
- 37 sites in United States, Australia and 6 more
- Volunteers
- 106 people
- Sponsor
- Gilead Sciences
Hepatitis C, Chronic
Vaniprevir Plus PegIntron®/Ribavirin in Japanese Participants With Chronic Hepatitis C Who Are Non-responders to Previous Treatment (MK-7009-045)
The purpose of this study is to evaluate the safety, tolerability, and efficacy of vaniprevir (300 mg twice daily) given in combination with pegylated interferon alfa-2b (peg-IFN) and ribavirin (RBV) in Japanese participants with…
- Trial name
- NCT01405560
- Testing
- Vaniprevir, peg-IFN, ribavirin
- Volunteers
- 42 people
- Sponsor
- Merck Sharp & Dohme LLC
Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis
A Phase III, Non-Inferiority, Randomized, Open-Label, Parallel Group, Multicenter Study To Investigate The Pharmacokinetics, Pharmacodynamics, Safety And Radiological And Clinical Effects Of Subcutaneous Ocrelizumab Versus Intravenous Ocrelizumab In Patients With Multiple Sclerosis
This study will evaluate the pharmacokinetics, pharmacodynamics, safety, immunogenicity, and radiological and clinical effects of subcutaneous (SC) administration of ocrelizumab compared with the intravenous (IV) infusion of…
- Trial name
- Ocarina II (NCT05232825)
- Testing
- Ocrelizumab IV, Ocrelizumab SC, Methylprednisolone IV
- Where
- 37 sites in United States, Brazil and 6 more
- Volunteers
- 236 people
- Sponsor
- Hoffmann-La Roche
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.